Spero Therapeutics (2HA) Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2HA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Spero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$1.47 |
| Beta | 1.46 |
| 1 Month Change | 4.02% |
| 3 Month Change | 8.75% |
| 1 Year Change | -8.10% |
| 3 Year Change | 42.20% |
| 5 Year Change | -82.06% |
| Change since IPO | -78.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2HA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.7% | 0.1% | -2.6% |
| 1Y | -8.1% | -7.7% | -1.4% |
Return vs Industry: 2HA matched the German Biotechs industry which returned -8% over the past year.
Return vs Market: 2HA underperformed the German Market which returned -0.8% over the past year.
Price Volatility
| 2HA volatility | |
|---|---|
| 2HA Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2HA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2HA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 25 | Esther Rajavelu | sperotherapeutics.com |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics, Inc. Fundamentals Summary
| 2HA fundamental statistics | |
|---|---|
| Market cap | €128.91m |
| Earnings (TTM) | €13.20m |
| Revenue (TTM) | €53.01m |
Is 2HA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2HA income statement (TTM) | |
|---|---|
| Revenue | US$61.19m |
| Cost of Revenue | US$27.77m |
| Gross Profit | US$33.42m |
| Other Expenses | US$18.18m |
| Earnings | US$15.24m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 54.61% |
| Net Profit Margin | 24.90% |
| Debt/Equity Ratio | 0% |
How did 2HA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 09:48 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spero Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |